Cart
sales@molnova.com
GSK-F1
CAS No. 1402345-92-9
GSK-F1( PI4KA inhibitor-F1 )
Catalog No. M27172 CAS No. 1402345-92-9
GSK-F1 is a novel potent PI4KA inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 357 | Get Quote |
|
| 10MG | 530 | Get Quote |
|
| 25MG | 851 | Get Quote |
|
| 50MG | 1152 | Get Quote |
|
| 100MG | 1557 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK-F1
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-F1 is a novel potent PI4KA inhibitor.
-
DescriptionGSK-F1 is a novel potent PI4KA inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsPI4KA inhibitor-F1
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI4K
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1402345-92-9
-
Formula Weight603.52
-
Molecular FormulaC27H18F5N5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (207.12 mM)
-
SMILESCOc1ncc(cc1S(=O)(=O)Nc1ccc(F)cc1F)-c1ccc2nc(N)n(-c3ccccc3C(F)(F)F)c(=O)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Murase A, et al. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci. 2008 Jan 16;82(3-4):226-232.
molnova catalog
related products
-
AZ044
AZ044 is a potent, selective inhibitor of type III phosphatidylinositol-4-kinase alpha-subtype (PI4KIIIalpha).
-
UCB9608
UCB9608 (UCB-9608) is a potent, selective, orally bioavailable PI4KIIIβ inhibitor with IC50 of 11 nM.
-
PI4KIIIβ-IN-9
PI4KIIIβ-IN-9 is a potent and selective inhibitor of PI4KIIIβ (IC50=7 nM).
